Check out our most popular compounded medications! Get Started
Morphine Sulfate 210 mg Slow Release Capsules are formulated with Methocel E4M, a controlled-release polymer. This design allows for the gradual release of the active ingredient over an extended period, providing sustained therapeutic effects. This formulation is used to treat various types of pain including chronic, cancer, postoperative, neuropathic, and arthritis pain. The slow release mechanism reduces dosing frequency and improves patient compliance for medications requiring a controlled and prolonged release profile.
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Morphine Sulfate 210 mg Slow Release Capsules are a potent, long-acting opioid analgesic designed to manage moderate to severe pain. This formulation is specifically engineered to provide a steady, consistent release of the active ingredient over an extended period of time, offering sustained therapeutic effects.
This formulation is particularly beneficial for patients requiring relief from pain associated with cancer, post-operative discomfort, and chronic pain conditions. However, it is not recommended for patients with acute pain, as the slow release mechanism may not provide immediate pain relief.
Patients should be aware that Morphine Sulfate 210 mg Slow Release Capsules may cause side effects such as drowsiness, dizziness, and confusion. It is advised not to drive or operate machinery while taking this medication. Furthermore, this medication has the potential to be habit-forming, and it is crucial not to take it for longer than prescribed.
Healthcare providers should note that Morphine Sulfate 210 mg Slow Release Capsules can cause respiratory depression and should be prescribed with caution in patients with respiratory conditions. It is also important to remember that this medication can be habit-forming, and it should be prescribed for the shortest duration possible to mitigate the risk of dependency.
If you have any questions or concerns about Morphine Sulfate 210 mg Slow Release Capsules, please do not hesitate to contact us at Bayview Pharmacy. We are here to provide you with the information and support you need to ensure safe and appropriate use of this medication.
Morphine Sulfate 210 mg Slow Release Capsules are a potent analgesic medication, specifically designed for the management of moderate to severe pain. The capsules are formulated with Methocel E4M, a type of controlled-release polymer. This innovative formulation allows for the gradual release of the encapsulated medication over an extended period of time, providing sustained therapeutic effects. This slow-release mechanism not only enhances the efficacy of the medication but also reduces the frequency of dosing, thereby improving patient compliance.
It is crucial to note that Morphine Sulfate 210 mg Slow Release Capsules should not be administered to patients with a known hypersensitivity to morphine or other opioids. Additionally, it is contraindicated in patients with significant respiratory depression. Regular monitoring for signs of respiratory depression, sedation, and hypotension is recommended during the course of treatment. Furthermore, vigilance for signs of opioid addiction, abuse, and misuse is necessary.
Special caution is advised when prescribing Morphine Sulfate 210 mg Slow Release Capsules to patients with renal or hepatic impairment, as well as in elderly patients, due to the potential for increased sensitivity to the effects of the medication. Patients should be counseled to avoid alcohol and other CNS depressants while on this medication, as it may potentiate the sedative effects. Additionally, patients should be advised to refrain from activities requiring mental alertness, such as driving or operating machinery, until they are fully aware of how this medication affects them.
As with any medication, it is important to use Morphine Sulfate 210 mg Slow Release Capsules responsibly and under the supervision of a healthcare professional. If you have any questions or concerns regarding this medication, please do not hesitate to reach out for further information.
Morphine Sulfate 210 mg Slow Release Capsules are a potent, extended-release opioid medication designed to manage moderate to severe pain. These capsules are formulated with Methocel E4M, a type of controlled-release polymer, which allows for the gradual release of the encapsulated medication over an extended period of time. This slow-release mechanism provides a steady level of pain relief throughout a 12-hour period, reducing the need for frequent dosing and enhancing patient compliance.
The capsules are to be taken orally, with or without food, once every 12 hours. It is crucial to adhere to the prescribed dosage, as deviations can lead to serious side effects. The capsules should not be crushed, chewed, or dissolved as this can cause a rapid release of the medication, increasing the risk of side effects.
However, they are not recommended for short-term pain relief, such as pain resulting from an injury or surgery.
Patients should be aware of potential side effects, which may include nausea, vomiting, constipation, dizziness, drowsiness, and confusion. There is also a risk of addiction, abuse, and overdose associated with this medication. Abrupt discontinuation of the medication can lead to withdrawal symptoms, hence any changes to the dosage should be done under medical supervision.
If you have any queries regarding Morphine Sulfate 210 mg Slow Release Capsules, please do not hesitate to contact us. We are a team of experienced compounding pharmacists ready to assist you.
Morphine Sulfate 210 mg Slow Release Capsules is a medication formulated with Methocel E4M, a type of controlled-release polymer. This formulation is designed to release the encapsulated medication gradually over an extended period of time.
The controlled-release polymer, Methocel E4M, is designed to release the medication gradually over an extended period of time. This offers sustained therapeutic effects, reduces dosing frequency, and improves patient compliance for medications requiring a controlled and prolonged release profile.
The benefits of using this medication include sustained therapeutic effects due to the gradual release of the medication, reduced dosing frequency, and improved patient compliance due to the controlled and prolonged release profile.
The slow release mechanism works by gradually releasing the encapsulated medication over an extended period of time. This is achieved through the use of a controlled-release polymer, Methocel E4M.
'Improved patient compliance' means that patients are more likely to take their medication as prescribed due to the reduced dosing frequency and the sustained therapeutic effects of the medication.
Methocel E4M is a type of controlled-release polymer used in the formulation of certain medications. It is designed to release the encapsulated medication gradually over an extended period of time.
'Sustained therapeutic effects' means that the medication continues to have its intended therapeutic effect over an extended period of time due to the gradual release of the medication.
The dosing frequency of Morphine Sulfate 210 mg Slow Release Capsules is reduced due to the controlled-release polymer, Methocel E4M. However, the exact dosing schedule should be determined by your healthcare provider.
No, Morphine Sulfate 210 mg Slow Release Capsules should not be broken or crushed. Doing so can interfere with the controlled-release mechanism and may lead to a rapid release and absorption of a potentially fatal dose of morphine.
If you miss a dose of Morphine Sulfate 210 mg Slow Release Capsules, take it as soon as you remember. If it is near the time of the next dose, skip the missed dose. Do not double the dose to catch up. Always consult your healthcare provider to ensure the information applies to your personal circumstances.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
This preparation is a controlled substance. Additional prescribing, refill, and shipping restrictions apply, and the states Bayview can dispense it to are narrower than for non-controlled preparations.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take 1 capsule by mouth
